Nxeo Sa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Onxeo S.A. Onxeo” or “ the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that it has received from the U.S. Patent and Trademark Office (USPTO), a Notice Allowance for a patent which enhances in the United States the protection of AsiDNA™, its first-in-class inhibitor of tumor DNA repair, in combination with any PARP inhibitor (PARPi). This patent protects both the combination of AsiDNA™ with a PARPi and its use for the treatment of certain cancers for which the DNA repair pathway via homologous recombination (HR) is not impaired or deficient. These so-called HR-proficient tumors are significantly less sensitive to treatment with PARP inhibitors.

United statesFrance generalNicolas merigeauOnxeo sa euronextValerie leroyJudith grecietEmmanuel huynhBrian ritchieTrademark officeEuronext parisNotice allowanceChief executive officerInhibitor administered intravenouslyNasdaq firstEnglj medEuropean medical oncology